600267.SH
海正药业
SSE · Healthcare · Drug Manufacturers - Specialty & Generic · CN
CNY 12.06
−7.80%Aug 28, 2026, 02:52 UTC
Hisun Pharmaceutical signed a strategic cooperation agreement with Chengdu Xingji Space Exploration Technology Co., Ltd. (Xingji Development) to enter the space biopharmaceutical sector.
Source:Aug 25, 2026, 09:45 UTC
Hisun Pharmaceutical announced its first-half 2026 results: net profit attributable to shareholders was 636 million yuan, up 112.82% year-on-year, with revenue of 4.475 billion yuan, down 14.76%.
Aug 18, 2026, 20:30 UTC
Chinese companies, including Fosun Pharma and Zhejiang Hisun Pharmaceutical, expressed interest in expanding partnerships with Jordan in pharmaceutical and food manufacturing, including joint ventures and R&D, during a meeting with King Abdullah in Shanghai.
Source:Aug 3, 2026, 07:32 UTC
Hisun Pharmaceutical and its wholly-owned subsidiary Hanhui Pharmaceutical participated in the bidding for the 12th national centralized drug procurement on July 31, 2026, with 5 products preliminarily selected, including imipenem and cilastatin sodium for injection, with procurement cycles lasting until December 31, 2029.
Source:Jul 3, 2026, 10:31 UTC
Zhejiang Hisun Pharmaceutical Co., Ltd. signed an exclusive license and cooperation agreement with Atia to develop, register, manufacture and commercialize the innovative chemical drug TISA-818 systemic formulation in Mainland China, Hong Kong and Macau.